Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.

Noopur RajeJesus BerdejaYi LinDavid S SiegelSundar JagannathDeepu MadduriMichaela LiedtkeJacalyn RosenblattMarcela V MausAshley TurkaLyh-Ping LamRichard A MorganKevin FriedmanMonica MassaroJulie WangGreg RussottiZhihong YangTimothy CampbellKristen HegeFabio PetroccaM Travis QuigleyNikhil MunshiJames N Kochenderfer

Published in: The New England journal of medicine (2019)

We report the initial toxicity profile of a BCMA-directed cellular immunotherapy for patients with relapsed or refractory multiple myeloma. Antitumor activity was documented. (Funded by Bluebird Bio and Celgene; CRB-401 ClinicalTrials.gov number, NCT02658929.).

Keyphrases

multiple myeloma
cell therapy
stem cells
mesenchymal stem cells
growth factor
bone marrow